EUVIMEDEUVIMED entdecken
Open Access

CDC42: unlocking a novel therapeutic target for primary sclerosing cholangitis through Mendelian randomization

Jie Zhou, Yixin Xu, Haitao Wang, Chao Chen, Kun Wang

American Journal of Translational Research · 2025 · 17 (2) · 1076-1086

DOI: 10.62347/btyn8678 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Translational Research, 2025. Verfasst von Jie Zhou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The Wujin Hospital Affiliated with Jiangsu University Changzhou 213003, Jiangsu, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This study seeks to identify new drug targets for Primary Sclerosing Cholangitis (PSC), a condition currently lacking effective treatment, to improve survival without transplantation.

Methods

We obtained summary statistics for 2,888 druggable genes and PSC from the eQTLGen Consortium and the FinnGen consortium, respectively.Through two-sample Mendelian randomization using the Inverse Variance Weighted (IVW) method, we identified genes associated with PSC at a False Discovery Rate (FDR) < 0.05.Further validation came from colocalization and Summary-data-based Mendelian Randomization (SMR) analyses, confirming the reliability of our results.

Results

Five druggable genes were causally associated with PSC at FDR < 0.05.Subsequent colocalization and SMR analyses further confirmed that higher levels of CDC42 in plasma were associated with an increased risk of PSC (IVW method: Odds Ratio 1.319, 95% Confidence Interval 1.182-1.471,P = 6.85E-07,FDR = 0.002).

Conclusions

Our research pioneered the identification of CDC42 as a target for slowing PSC progression.Our research not only uncovers a possible drug target but also provides direction for the development of therapeutics for PSC.

Schlagwörter

Stichwörter der Autor:innen

M2 macrophagescausal relationshipcholangitisdruggable genessingle nucleotide polymorphism

Autor:innen und Institutionen

  • Department of General Surgery, The Wujin Hospital Affiliated with Jiangsu University Changzhou 213003, Jiangsu, China.
  • Department of General Surgery, The Wujin Clinical College of Xuzhou Medical University Changzhou 213003, Jiangsu, China.
  • Department of General Surgery, The Third Affiliated Hospital of Soochow University Changzhou 213003, Jiangsu, China.

Zitieren

APA

Zhou, J., Xu, Y., Wang, H., Chen, C., & Wang, K. (2025). CDC42: unlocking a novel therapeutic target for primary sclerosing cholangitis through Mendelian randomization. American Journal of Translational Research, 17(2), 1076-1086. https://doi.org/10.62347/btyn8678

Vancouver

Zhou J, Xu Y, Wang H, Chen C, Wang K. CDC42: unlocking a novel therapeutic target for primary sclerosing cholangitis through Mendelian randomization. American Journal of Translational Research. 2025;17(2):1076-1086. doi:10.62347/btyn8678

BibTeX
@article{Zhou2025,
  author = {Zhou, Jie and Xu, Yixin and Wang, Haitao and Chen, Chao and Wang, Kun},
  title = {CDC42: unlocking a novel therapeutic target for primary sclerosing cholangitis through Mendelian randomization},
  journal = {American Journal of Translational Research},
  year = {2025},
  volume = {17},
  number = {2},
  pages = {1076--1086},
  doi = {10.62347/btyn8678}
}
Kostenlos starten →